康柏西普治疗糖尿病视网膜病变有效性及安全性的meta分析  

Efficacy and safety of conbercept for diabetic retinopathy:a meta-analysis

作　　者：司霞[1] 田攀攀 于芝颖[1] 冯婉玉[1] SI Xia,TIAN Pan-pan, YU Zhi-ying, FENG Wan-yu(Department of Pharmacy, Peking University People＇s Hospital, Beijing 100044, China)

机构地区：[1]北京大学人民医院药剂科,北京100044

出　　处：《临床药物治疗杂志》2018年第9期48-53,63,共7页Clinical Medication Journal

摘　　要：目的:系统评价玻璃体腔注射康柏西普治疗糖尿病视网膜病变的临床疗效及安全性。方法:计算机检索Embase、Pubmed、Cochrane library、中国知网、万方数据库及维普数据库中已发表的关于对比康柏西普和曲安奈德治疗糖尿病视网膜病变的随机对照试验,采用RevMan5.3软件进行meta分析。结果:最终纳入11篇RCT文献,共994眼,其中康柏西普组498眼,曲安奈德组496眼。Meta分析结果显示,治疗后康柏西普组患者的最佳矫正视力高于曲安奈德组,差异具有统计学意义(随访1个月:RR=0.03,95%CI:0.02～0.05,P<0.01;随访3个月:RR=0.18,95%CI:0.16～0.19,P<0.01)。治疗后康柏西普组患者的视网膜厚度小于曲安奈德组,差异有统计学意义(随访1个月:RR=-154.82, 95%CI:-170.41～-139.23, P<0.01;随访3个月:RR=-141.02, 95%CI:-210.89～-71.16,P<0.01)。康柏西普组治疗后前房角膜炎、角膜水肿和眼压升高的发生率低于曲安奈德组(P<0.01)。康柏西普组患者自理能力、活动能力、社交和心理评分高于曲安奈德组(P <0.01)。结论:玻璃体腔注射康柏西普治疗糖尿病视网膜病变的疗效较好,安全性高,可以显著提高患者的生活质量。Objective： To evaluate the efficacy and safety of intravitreal conbercept for diabetic retinopathy （DR） with meta- analysis. Methods： A systematic search in Embase, Pubmed, Cochrane library, CNKI, Wanfang and VIP database, randomized cotrolled trials （RCTs） on the comparison of conbercept with triamcinolone acetouide for the clinical effect and safety of DR were collected RevMan 5.3 was applied for data analysis. Results： A total of 11 RCTs involving 994 eyes were included, including 498 eyes in the conbercept group and 496 eyes in the triamcinolone acetonide group. Meta-analysis showed that the best corrected visual acuity （BCVA） was significantly higher in the conbercept group than in the triarncinolone acetonide group （RR =0.03, 95%CI ： 0.02-0. 05, P〈0.01 at 1 month after treatment andRR =0. 18, 95%CI ： 0. 16 -0. 19, P〈 0. 01 at 3 months after treatment） . A greater reduction of retinal thickness was observed in the conbercept group than in the triarncinoloue acetonide group （RR =-154.82 , 95%CI： -170. 41- -139. 23, P〈0. 01 at 1 month after treatment and RR = -141.02, 95%CI： -210.89 --71.16, P〈 0. 01 at 3 months after treatment） . The incidences of anterior chamber inflammation reaction, corneal edema and high intraocular pressure of conbercept group were lower than those in the triarncinolone acetonide group （ P 〈 0.01） . The conbercept group of self-help ability, health activity ability, daily sociability and mental ability scores were higher than the triarncinolone acetonide group （P 〈0. 01） . Conclusion： Intravitreal conbercept showed better effects than triamcinolone acetonide in treating DR, it can significantly enhance the life quality of patients and with higher safety.

关 键 词：康柏西普 糖尿病视网膜病变 曲安奈德 血管内皮生长因子 META分析 

分 类 号：R969.3[医药卫生—药理学]